Connect your AI

Lucid Diagnostics LUCD Other Commercial Liabilities

Other Commercial Liabilities at other companies

Guardant HealthGH

——

Biodesix, Inc.BDSX

——

Insight Molecular Diagnostics Inc. Common StockIMDX

——

Fulgent Genetics, Inc.FLGT

——

GeneDx HoldingsWGS

——

Labcorp HoldingsLH

——

Other financials

Income statement

Revenue$1.3M+51.7%

Gross profit-$369.0K+49.0%

Operating income-$12.1M+3.0%

Net income-$13.9M+48.3%

EPS (diluted)-$0.10+60.0%

Balance sheet

Cash & equivalents$27.9M+10.6%

Total debt$1.6M-35.1%

Total equity$4.0M+174%

Total assets$34.1M+3.9%

Cash flow

Operating cash flow-$12.1M+2.9%

CapEx$215.0K+131%

Free cash flow-$12.3M+1.9%

Valuation

Market cap$204.13M+58.5%

Enterprise value$177.85M+78.0%

P/S39.8×+10.2×

Profitability

Gross margin-66.8%—

Operating margin-959.6%-133pp

Net margin-876.7%-254pp

FCF margin-1,099.6%—

Returns & leverage

Return on equity-710.6%—

Debt / equity0.4×—

Current ratio1.1×+0.3×

Where this comes from

Reported directly by Lucid Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lucid Diagnostics's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Lucid Diagnostics's other commercial liabilities?: Lucid Diagnostics (LUCD) reported other commercial liabilities of $2.2M in Q1 2026.